Status and phase
Conditions
Treatments
About
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus is an FDA-approved medication which may improve the blood flow to the brain. This study is designed to see if sirolimus treatment improves MRI blood flow to the brain in individuals with and without a genetic predisposition to Alzheimer's disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
105 participants in 2 patient groups
Loading...
Central trial contact
Jessica Overschmidt; Joanne Cassani
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal